AstraZeneca won a key US regulatory milestone as the FDA approved Baxfendy (baxdrostat), an aldosterone synthase inhibitor, for patients with hypertension that remains inadequately controlled on other therapies. The approval positions AstraZeneca to extend revenue momentum as older cardiometabolic assets approach patent milestones. The FDA’s clearance was supported by data from the phase III BaxHTN study, which met primary and secondary endpoints, according to coverage of the decision. The new mechanism of action also sets up near-term competitive pressure, with Mineralys Therapeutics’ lorundrostat cited as a potential upcoming rival in the same drug class. For clinicians and trial designers, the approval adds a new pharmacologic option in combination regimens—potentially influencing payer discussions and further label positioning for aldosterone-pathway targeting.